Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644328 | 0.98 | HRH3 (0.69) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL16644362 | 0.98 | HRH3 (0.69) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL15467001 | 0.89 | HRH3 (0.87) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL13061370 | 0.85 | HRH3 (0.67) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL11864 | 0.84 | HRH3 (0.71) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL19251384 | 0.84 | HRH3 (0.53) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL14787825 | 0.82 | HRH3 (0.69) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL14791028 | 0.82 | HRH3 (0.69) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL25137036 | 0.82 | HRH3 (0.62) | HRH3SMN1; SMN2POLBNOS3NOS1 | |
| SCHEMBL10235392 | 0.82 | NCF1 (0.71) | HRH3SMN1; SMN2NOS1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | disclosed |
| EP-3772513-A1 | SHP2 INHIBITORS | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2021-02-10 | — | — | EP | disclosed |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7241769-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | HRH3 3715/4885SMN1; SMN2 3416/4885POLB 635/4885 |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | HRH3 1151/4885SMN1; SMN2 111/4885POLB 352/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | HRH3 1487/4885SMN1; SMN2 4746/4885POLB 1540/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HRH3 1972/4885SMN1; SMN2 3557/4885POLB 450/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | HRH3 2011/4885SMN1; SMN2 2187/4885POLB 4123/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | HRH3 2011/4885SMN1; SMN2 2187/4885POLB 4123/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | HRH3 1487/4885SMN1; SMN2 4746/4885POLB 1540/4885 |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | HRH3 4538/4885SMN1; SMN2 3570/4885POLB 3401/4885 |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | HRH3 1502/4885SMN1; SMN2 21/4885POLB 4540/4885 |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | HRH3 3033/4885SMN1; SMN2 1119/4885POLB 709/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | HRH3 948/4885SMN1; SMN2 3187/4885POLB 2944/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | HRH3 3186/4885SMN1; SMN2 2933/4885POLB 18/4885 |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | HRH3 3033/4885SMN1; SMN2 1119/4885POLB 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.